WO2003080102A1 - Metodo para la estimulacion del crecimiento y resistencia a enfermedades en orgamismos acuaticos - Google Patents
Metodo para la estimulacion del crecimiento y resistencia a enfermedades en orgamismos acuaticos Download PDFInfo
- Publication number
- WO2003080102A1 WO2003080102A1 PCT/CU2003/000002 CU0300002W WO03080102A1 WO 2003080102 A1 WO2003080102 A1 WO 2003080102A1 CU 0300002 W CU0300002 W CU 0300002W WO 03080102 A1 WO03080102 A1 WO 03080102A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- growth
- ghrp
- diseases
- resistance
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 18
- 201000010099 disease Diseases 0.000 title claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
- 230000004936 stimulating effect Effects 0.000 title claims description 9
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 claims abstract description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 46
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 claims abstract description 26
- 241000251468 Actinopterygii Species 0.000 claims abstract description 21
- 235000019688 fish Nutrition 0.000 claims abstract description 21
- 241000238424 Crustacea Species 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims description 30
- 238000007654 immersion Methods 0.000 claims description 24
- 241000238557 Decapoda Species 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 241000530454 Litopenaeus schmitti Species 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 241000972773 Aulopiformes Species 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000019515 salmon Nutrition 0.000 claims description 4
- 241000530452 Litopenaeus Species 0.000 claims description 3
- 241000276719 Oreochromis Species 0.000 claims description 3
- 244000078703 ectoparasite Species 0.000 claims description 3
- 244000000013 helminth Species 0.000 claims description 3
- 230000017363 positive regulation of growth Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 208000030852 Parasitic disease Diseases 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 241000238554 Penaeus sp. Species 0.000 claims 1
- 241000028606 Trichodina sp. Species 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 244000052769 pathogen Species 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 229940088597 hormone Drugs 0.000 abstract description 5
- 230000007123 defense Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 241000276707 Tilapia Species 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 23
- 108010051696 Growth Hormone Proteins 0.000 description 9
- 102100038803 Somatotropin Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000122 growth hormone Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 230000009545 invasion Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 230000001418 larval effect Effects 0.000 description 7
- 230000000580 secretagogue effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012353 t test Methods 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 238000009360 aquaculture Methods 0.000 description 6
- 244000144974 aquaculture Species 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000238582 Artemia Species 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000237852 Mollusca Species 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 2
- 241001611011 Caligus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 241000277331 Salmonidae Species 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 1
- 241001672739 Artemia salina Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 238000010159 Duncan test Methods 0.000 description 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102400000243 Leu-enkephalin Human genes 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 241000238553 Litopenaeus vannamei Species 0.000 description 1
- 241001124325 Marsupenaeus japonicus Species 0.000 description 1
- 102400000988 Met-enkephalin Human genes 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241001500087 Trichodina Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Definitions
- the invention is related to the application of chemical synthesis to increase the efficiency of the growth of fish and crustaceans of commercial value.
- the synthesis of analog peptides of the Leu-enkephalin and Met-enkephalin type has been reported and its ability to stimulate the release of growth hormone in mammals and birds has been demonstrated (Bowers C, Momany, G, Reynolds G and A. Hong 1984. Endocrinology 114: 1537-45).
- Aquaculture 173, 10 making it one of the most important applications In penetrated shrimp it could be genetic engineering focused on improving growth and increasing its resistance to pathogens (Bachere, E., Mialhe, E., Noel, D., Boulo, V., Morvan, A., Rodr ⁇ guez , J. (1995) Aquaculture ⁇ 32, 17-32).
- the GHRP-6 peptide is capable of stimulating growth alone, improving larval quality, increasing defenses against pathogens, increasing dry weight, protein concentration and RNA in fish muscle. , crustaceans and mollusks.
- the use of the GHRP-6 peptide for growth stimulation and resistance to pathogens and other diseases is presented for the first time. It is also demonstrated that the GHRP-6 secretagogue alone stimulates growth in fish and crustaceans by injection, orally or by immersion. It also demonstrates its effect on the defense against pathogens, the increase of dry weight in the muscle of the treated aquatic organisms, the increase in the concentration of proteins and RNA in the tissue and the maintenance of erythrocytes as a demonstration of their safety in tilapia
- FIG. 5 Growth experiment in Litopenaeus schmitti shrimp treated with the GHRP-6 peptide.
- A Profile of weight gain in milligrams of shrimp in the three groups treated with the peptide and the control group.
- B Profile of increase in millimeter length of shrimp in the three groups treated with the peptide and the control group.
- C Distribution of the absolute frequency of the branchial branches of three groups treated with the peptide and the control group.
- D Distribution of the absolute frequency of the rostral modifications of three groups treated with the peptide and the control group.
- I, II, 111 Groups treated with different concentrations of peptide. Grpo control treated with BSA.
- FIG. 7 Relationships between RNA, Protein and DNA. As can be seen in the figure, there are significant differences in what the hypertrophy of these parameters says in animals treated with peptide. *** t-test p ⁇ 0.001. The bars indicate the variation in weight ( ⁇ DS).
- hypothalamus-pituitary-white organ liver
- the GHRP-6 secretagogue was tested in shrimp Litopenaeus schmitti, demonstrating that it was able to stimulate shrimp growth from its application of 4 immersion baths, in different larval stages.
- the groups treated with doses similar to tilapia had a higher quality. This was evidenced by an increase in weight, increase in height, a greater number of pairs of branchial branches and rostral modifications, a lower water content in the muscle of animals and a higher concentration of protein RNA in the muscle which evidenced a increased metabolic activity
- the larvae treated with the peptide and the control were planted in land ponds to see their productive behavior. On the day of the harvest of the ponds, the animals treated with the peptide maintained the increase in weight, height and greater homogeneity in weight and height in this group when compared with the control.
- the GHRP-6 secretagogue was tested in shrimp Litopenaeus schmitti, demonstrating that it is capable of stimulating shrimp growth by intramuscular injection, in adult shrimp. At the end of the 15 days of the experiment, the injected peptide stimulated the growth of individuals between 100-150% compared to the control. With significant differences (p ⁇ 0.001).
- the GHRP-6 secretagogue was tested in shrimp Litopenaeus schmitti, demonstrating that it is capable of stimulating growth in shrimp orally, in shrimp larvae.
- the peptide GHRP-6 included in the diet increased shrimp growth by 30-40% compared to the control. With highly significant differences (p ⁇ 0.001).
- the bioencapsulated GHRP-6 secretagogue in saline anemia increased the growth of individuals between 30 and 40% compared to the control. With highly significant differences (p ⁇ 0.001). EXAMPLES OF REALIZATION
- Example 1 Demonstration of the biological activity of GHRP-6 in fish.
- tilapia average weight 71 ⁇ 28g were used for the experiment.
- the GHRP-6 peptide was injected at a concentration of 0.1 ⁇ g / gbw (micrograms of peptide per gram of animal weight).
- Liver and blood samples were collected before treatment and 15, 30, 60 and 360 minutes after peptide injection (three animals were used at each time). Serum and blood were frozen and stored at -70 ° C until they were used for the ELISA for the quantification of circulating GH or for the extraction of messenger RNA in the case of the liver for quantification by Southern blot of the levels of IGF-I.
- Total liver RNA from the tilapia used in the experiment was purified according to the protocol described by Chomczvnski and Sacchi. 20 ⁇ g of total RNA were applied and run on a 1% agarose-formaldehyde gel, finally transferred to a Nylon membrane (Hybond N, Amersham UK) and hybridized with a labeled probe corresponding to the complementary DNA of IGF-I tilapia ⁇ 6 ⁇ and then re-hybridized with a probe of the human glyceraldehyde 3 phosphate dehydrogenase gene (GADPH, kindly donated by Dr. Bryan Williams, Cleveland Foundation, OH, USA), for signal normalization.
- the hybridization signals were quantified from the digital processing of the radiography image, using the "Hewlett Packard Scanjet Plus scanner". The images were processed with the computer program "Bandleader".
- the serum GH levels of the injected tilapia were measured by an ELISA, using two monoclonal antibodies against tiGH (Mu ⁇ oz and cois, in preparation).
- Example 2 Growth experiment in juvenile tilapia treated with GHRP-6
- the GHRP-6 peptide (BACHEM, Switzerland) was diluted in sodium phosphate buffer solution
- PBS PBS
- peptide was applied to a group of 8 male tilapia with an average weight of 61.41 ⁇ 14.36 g and a control group of 7 male tilapia with an average weight of 61.58 ⁇ 29.67g was used and received PBS.
- the average weight was measured each week ( Figure 1). All animals in the experiment were marked with microchips (Stoelting Co. Wood Dale, EU).
- Peptide GHRP-6 (BACHEM, Switzerland) was diluted in PBS and administered orally through a plastic tube to the pharyngeal cavity to a group of 7 male tilapia that had an average weight of 84.66 ⁇ 12.2 g
- a control group of 7 male tilapia with an average weight of 86.38 ⁇ 6.26g was taken, which was given PBS under the same conditions as the group treated with the peptide.
- the treatment was carried out twice a week, for three weeks, administering a dose of 0.1 ⁇ g of peptide / g of wet weight of each fish (gbw) The average weight was measured every week ( Figure 2). All animals in the experiment were labeled with microchips (Stoelting Co. Wood Dale, E.U.).
- Table 5 Values of moisture percentage in muscle tissue. Immersion experiment with the GHRP-6 peptide in tilapia weighing 1g over a period of 45 days.
- Table 6 Values of protein concentration in muscle tissue. Immersion experiment with the GHRP-6 peptide in tilapia weighing 1g over a period of 45 days
- GHRP-6 peptide 50 microL injections of the GHRP-6 peptide were made between the first and second abdominal segments using an insulin syringe. The injections are performed once every 3 days using 1 microg / g of the weight of the GHRP-6 peptide. The control group was injected with 1 microg / g BSA weight. 15 animals were used for each group. The effect of the GHRP-6 peptide was estimated by measuring the length of the carapace with a king's foot and weighed at a weight of 0.1 g error.
- the animals were placed in nylon bags (0.8 cm of mesh light) with dimensions of 2 x 2 x 1 (length x width x height) in an earthen pond with a salinity of 30 gL-1, 25 C and natural photoperiod .
- the effect of the GHRP-6 peptide was estimated by measuring the length of the king's foot carapace and weighed at a weight of 0.1 g error.
- the GHRP-6 injected at the different concentrations increased the growth of individuals between 100 - 150% compared to the control. With significant differences (p ⁇ 0.001).
- the GHRP-6 peptide was included in a diet for postiarvas of 1% crustaceans.
- the GHRP-6 peptide included in the diet was microencapsulated by a complex coacervation method (Knorr D. and M. Daly. (1988). Process Biochemistry; 48-50). Subsequently, Litopenaeus schmitti postiarvas were fed with the aforementioned diet, as well as a control with BSA included in the feed.
- the effect of tiGH was estimated by measuring the length of the carapace of the larvae and post-larvae with an optical micrometer and weighed at a weight of 0.1 mg of error.
- the GHRP-6 peptide included in the diet increased shrimp growth by 30-40% compared to the control. With highly significant differences (p ⁇ 0.001).
- the GHRP-6 peptide was bioencapsulated in Artemia with which the post-larvae of Litopenaeus schmitti and Litopenaeus vanamei were fed.
- Artemia saline To bioencapsulate the GHRP-6 peptide in Artemia saline, it was added at a concentration of 10 mg / L for 1 hour and harvested and washed. Subsequently, the post-larvae of Litopenaeus schmitti were fed with this Artemia four times a day for a month of experimentation.
- the control group was fed with Saline Arthremia with bioencapsulated BSA.
- the effect of the GHRP-6 peptide was estimated by measuring the length of the carapace of the larvae and post-larvae with an optical micrometer and weighed at a weight of 0.01 mg of error.
- the bioencapsulated GHRP-6 peptide in Artemia salina increased the growth of individuals between 30 and 40% compared to the control. With highly significant differences (p ⁇ 0.001).
- Example 7. Growth experiment on salmon larvae (salmon salmon) by immersion baths with the peptide GHRP-6 Three groups of salmon larvae (salmon salmon) were taken and six immersion baths were applied, one every three days of one hour long with different concentrations of the GHRP-6 peptide at two of them and one group was taken as control. The concentrations of the peptide used were: 0.01 and 0.1 mg / L, in groups I and II respectively, the control group was given the same frequency of immersion baths with BSA at 1 mg / L.
- Example 8 Effectiveness of peptide GHRP-6 on the ectoparasite "sea lice” Caliaus sp. in trout (Oncorhvnchus mvkiss).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Insects & Arthropods (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Farming Of Fish And Shellfish (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60310203T DE60310203D1 (de) | 2002-01-24 | 2003-01-22 | Verfahren zur stimulierung des wachstums und des widerstands gegen erkrankungen von wasserorganismen |
JP2003577928A JP4195865B2 (ja) | 2002-01-24 | 2003-01-22 | 水生生物の成長促進および病気に対する抵抗力の向上のための方法 |
US10/501,697 US8852601B2 (en) | 2002-01-24 | 2003-01-22 | Method of stimulating growth and resistance to diseases of aquatic organisms |
KR1020047011367A KR100953778B1 (ko) | 2002-01-24 | 2003-01-22 | 수생 생물의 성장 촉진 및 질병에 대한 내성화 방법 |
BR0307092-1A BR0307092A (pt) | 2002-01-24 | 2003-01-22 | Método para estimular o crescimento e a resistência a enfermidades em organismos aquáticos e formulação veterinária para estimular o crescimento e a resistência a enfermidades em peixes e crustáceos |
AU2003210124A AU2003210124A1 (en) | 2002-01-24 | 2003-01-22 | Method of stimulating growth and resistance to diseases of aquatic organisms |
EP03744706A EP1477181B1 (en) | 2002-01-24 | 2003-01-22 | Method of stimulating growth and resistance to diseases of aquatic organisms |
DK03744706T DK1477181T3 (da) | 2002-01-24 | 2003-01-22 | Fremgangsmåde til stimulering af vækst og modstandsdygtighed over for syddomme hos akvatiske orgsnismer |
MXPA04006940A MXPA04006940A (es) | 2002-01-24 | 2003-01-22 | Metodo para la estimulacion del crecimiento y resistencia a enfermedades en organismos acuaticos.. |
CA2473973A CA2473973C (en) | 2002-01-24 | 2003-01-22 | Method of stimulating growth and resistance to diseases of aquatic organisms |
CN03802778XA CN1622821B (zh) | 2002-01-24 | 2003-01-22 | 刺激水生生物生长及抗病性的方法 |
BRPI0307092A BRPI0307092B1 (pt) | 2002-01-24 | 2003-01-22 | formulação veterinária para estimular o crescimento e a resistência a enfermidades em peixes e crustáceos |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2002002020020020A CU23016A1 (es) | 2002-01-24 | 2002-01-24 | Método para la estimulación del crecimiento y resimétodo para la estimulación del crecimiento y resistencia a enfermedades en organismos acuáticos y fstencia a enfermedades en organismos acuáticos y formulación veterinaria ormulación veterinaria |
CU2002/0020 | 2002-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003080102A1 true WO2003080102A1 (es) | 2003-10-02 |
Family
ID=28050593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2003/000002 WO2003080102A1 (es) | 2002-01-24 | 2003-01-22 | Metodo para la estimulacion del crecimiento y resistencia a enfermedades en orgamismos acuaticos |
Country Status (17)
Country | Link |
---|---|
US (1) | US8852601B2 (es) |
EP (1) | EP1477181B1 (es) |
JP (1) | JP4195865B2 (es) |
KR (1) | KR100953778B1 (es) |
CN (1) | CN1622821B (es) |
AR (1) | AR038310A1 (es) |
AT (1) | ATE347369T1 (es) |
AU (1) | AU2003210124A1 (es) |
BR (2) | BRPI0307092B1 (es) |
CA (1) | CA2473973C (es) |
CU (1) | CU23016A1 (es) |
DE (1) | DE60310203D1 (es) |
DK (1) | DK1477181T3 (es) |
EC (1) | ECSP045186A (es) |
ES (1) | ES2277097T3 (es) |
MX (1) | MXPA04006940A (es) |
WO (1) | WO2003080102A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050114004A (ko) * | 2004-05-31 | 2005-12-05 | (주)진투프로테인 | 재조합 소 성장 호르몬을 이용한 새우의 면역증강 및 성장촉진 방법 |
CU23557A1 (es) * | 2005-11-22 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Neuropéptidos para el cultivo de organismos acuáticos |
CU23634A1 (es) * | 2007-05-31 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Secuencias de ácido nucleico y aminoácidos, y vacuna para el control de infestaciones por ectoparásitos en peces |
TWI398219B (zh) * | 2009-12-10 | 2013-06-11 | Univ Nat Pingtung Sci & Tech | 一種藻酸鈉用於提升對蝦屬生殖能力之用途 |
CU24473B1 (es) | 2016-11-01 | 2020-02-04 | Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma | Composición vacunal que comprende un péptido secretagogo de la hormona de crecimiento como adyuvante vacunal |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4411890A (en) * | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
ES2005224A6 (es) * | 1986-05-12 | 1989-03-01 | Eastman Kodak Co | Combinacion de polipeptidos para liberar y aumentar la hormona de crecimiento en la sangre de un animal. |
US5767124A (en) * | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5486505A (en) | 1990-07-24 | 1996-01-23 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
EP0650597A4 (en) * | 1992-06-29 | 1996-12-18 | Univ South Florida | DIAGNOSTIC PROCEDURE FOR EVALUATING THE ETIOLOGY OF STATURAL INSUFFICIENCY. |
EP0761220A1 (en) * | 1995-08-21 | 1997-03-12 | Eli Lilly And Company | 2-Acylaminopropanamides as growth hormone secretagogues |
US5972895A (en) * | 1996-12-11 | 1999-10-26 | A. Glenn Braswell | Composition and method for increasing growth hormone levels |
DE19828924C1 (de) * | 1998-06-29 | 1999-06-02 | Siemens Ag | Schaltungsanordnung zum Steuern eines Fahrwerks- oder Antriebssystems in einem Kraftfahrzeug |
-
2002
- 2002-01-24 CU CU2002002020020020A patent/CU23016A1/es unknown
-
2003
- 2003-01-22 CA CA2473973A patent/CA2473973C/en not_active Expired - Lifetime
- 2003-01-22 AU AU2003210124A patent/AU2003210124A1/en not_active Abandoned
- 2003-01-22 CN CN03802778XA patent/CN1622821B/zh not_active Expired - Fee Related
- 2003-01-22 DK DK03744706T patent/DK1477181T3/da active
- 2003-01-22 KR KR1020047011367A patent/KR100953778B1/ko active IP Right Grant
- 2003-01-22 ES ES03744706T patent/ES2277097T3/es not_active Expired - Lifetime
- 2003-01-22 DE DE60310203T patent/DE60310203D1/de not_active Expired - Lifetime
- 2003-01-22 WO PCT/CU2003/000002 patent/WO2003080102A1/es active IP Right Grant
- 2003-01-22 MX MXPA04006940A patent/MXPA04006940A/es active IP Right Grant
- 2003-01-22 BR BRPI0307092A patent/BRPI0307092B1/pt unknown
- 2003-01-22 EP EP03744706A patent/EP1477181B1/en not_active Expired - Lifetime
- 2003-01-22 AT AT03744706T patent/ATE347369T1/de not_active IP Right Cessation
- 2003-01-22 JP JP2003577928A patent/JP4195865B2/ja not_active Expired - Fee Related
- 2003-01-22 BR BR0307092-1A patent/BR0307092A/pt not_active IP Right Cessation
- 2003-01-22 US US10/501,697 patent/US8852601B2/en active Active
- 2003-01-23 AR ARP030100200A patent/AR038310A1/es not_active Application Discontinuation
-
2004
- 2004-07-12 EC EC2004005186A patent/ECSP045186A/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4411890A (en) * | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
ES2005224A6 (es) * | 1986-05-12 | 1989-03-01 | Eastman Kodak Co | Combinacion de polipeptidos para liberar y aumentar la hormona de crecimiento en la sangre de un animal. |
US5767124A (en) * | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
Also Published As
Publication number | Publication date |
---|---|
JP2005519972A (ja) | 2005-07-07 |
EP1477181A1 (en) | 2004-11-17 |
CN1622821B (zh) | 2012-10-10 |
BR0307092A (pt) | 2004-12-28 |
EP1477181B1 (en) | 2006-12-06 |
CA2473973A1 (en) | 2003-10-02 |
ATE347369T1 (de) | 2006-12-15 |
KR100953778B1 (ko) | 2010-04-21 |
AU2003210124A1 (en) | 2003-10-08 |
DE60310203D1 (de) | 2007-01-18 |
BRPI0307092B1 (pt) | 2018-11-21 |
JP4195865B2 (ja) | 2008-12-17 |
MXPA04006940A (es) | 2004-12-06 |
US20060234905A1 (en) | 2006-10-19 |
US8852601B2 (en) | 2014-10-07 |
CA2473973C (en) | 2011-01-04 |
DK1477181T3 (da) | 2007-04-10 |
CU23016A1 (es) | 2005-01-25 |
KR20040094676A (ko) | 2004-11-10 |
ECSP045186A (es) | 2004-08-27 |
AR038310A1 (es) | 2005-01-12 |
ES2277097T3 (es) | 2007-07-01 |
CN1622821A (zh) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2326595T3 (es) | Composicion de pienso para animales. | |
McLean et al. | Gastrointestinal delivery of peptide and protein drugs to aquacultured teleosts | |
Marte et al. | Induced spawning of maturing milkfish (Chanos chanos Forsskal) with gonadotropin-releasing hormone (GnRH) analogues administered in various ways | |
Boeuf et al. | Control of the somatic growth in turbot | |
TW201417718A (zh) | 用於改善動物健康的方法 | |
Farmanfarmaian et al. | Growth hormone effects on essential amino acid absorption, muscle amino acid profile, N-retention and nutritional requirements of striped bass hybrids | |
JP5771203B2 (ja) | 魚類の寄生虫駆除剤及び駆除方法 | |
Putra et al. | Growth increase of silver pompano (Trachinotus blochii) stimulated by recombinant growth hormone (rGH) addition on their commercial feed | |
ES2277097T3 (es) | Procedimiento de estimulacion de crecimiento y resistencia a las enfermedades de organismos acuaticos. | |
PT1956031E (pt) | Neuropéptidos para a cultura de organismos aquáticos | |
Marte et al. | Induced spawning of maturing milkfish (Chanos chanos) using human chorionic gonadotropin and mammalian and salmon gonadotropin releasing hormone analogues | |
WO2016063105A1 (es) | Composición para el tratamiento de ectoparasitosis y la promoción del crecimiento en acuicultura | |
Vazirzadeh et al. | Spawning induction in doctor fish, Garra rufa (Heckel, 1843) by Ovaprim and captive rearing of larvae | |
Amini et al. | Evaluation of LHRH-a acute release implantation on final maturation and spawning in not-fully matured broodstocks of Persian sturgeon (Acipenser persicus Borodin, 1897) | |
CA1254437A (en) | Growth stimulant for animals | |
JP2001081034A (ja) | 動物用抗原虫剤 | |
Burns | Effects of Swimming and Creatine Supplementation on Cultured Fishes | |
WO2022226660A1 (en) | Use of isoxazoline for protection against parasitic pests in fish | |
Husen et al. | Efficacy of Clove Oil for Safe Carp Fish Seed Transportation | |
Nayak et al. | Evaluation of the potential for using hGH to enhance growth in juvenile Catla catla | |
López-Olmeda et al. | Welfare, Stress and Immune System | |
JPH10313727A (ja) | フグの養殖方法 | |
Teskeredžić et al. | Intact Protein Absorption by the Fish Gut. 2. Application Potential and Limitations | |
Martemyanov | Physiological and biochemical basis of salmon young fishes migratory behavior | |
Teskeredžić | Z. Teskeredžić, E. Teskeredžić, E. McLean, R. Ash |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/006940 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2473973 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047011367 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003577928 Country of ref document: JP Ref document number: 1-2004-501116 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003802778X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1849/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003744706 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200400810 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003744706 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006234905 Country of ref document: US Ref document number: 10501697 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10501697 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003744706 Country of ref document: EP |